Assembly of Alzheimer's amyloid-β fibrils and approaches for therapeutic intervention

Amyloid

Volumn 8, Issue SUPPL. 1, 2001, Pages 10-19

  Yang, D S ^a   Serpell, L C ^a   Yip, C M ^a   McLaurin, J ^a   Chrishti, M A ^a   Horne, P ^a   Boudreau, L ^a   Kisilevsky, R ^a   Westaway, D ^a   Fraser, P E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Amyloid ; Fibril formation; Heparan sulfate proteoglycans; Senile plaques; Transgenic mice

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; GLYCOSAMINOGLYCAN POLYSULFATE; PROTEOGLYCAN; PROTEOHEPARAN SULFATE; THIOFLAVINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BETA SHEET; CLINICAL FEATURE; CONFERENCE PAPER; ELECTRON MICROSCOPY; IMMUNOCYTOCHEMISTRY; MOUSE; NEUROPIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; SENILE PLAQUE; TRANSGENIC ANIMAL; X RAY DIFFRACTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; MACROMOLECULAR SUBSTANCES; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, ATOMIC FORCE; MOLECULAR STRUCTURE; PROTEOGLYCANS; X-RAY DIFFRACTION;

EID: 0034826758     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (87)

1. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17
2. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
3. Proteolytic processing and cell biological functions of the amyloid precursor protein
4. Regulation of Alzheimer beta-amyloid precursor trafficking and metabolism
5. Neurodegeneration induced by betaamyloid peptides in vitro: The role of peptide assembly state
6. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red
7. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid
8. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease
9. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants
10. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1
11. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo
12. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
13. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice
14. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
15. Production of the Alzheimer amyloid beta protein by normal proteolytic processing
16. Modulating factors in amyloid-b fibril formation
17. Binding of human apolipoprotein E to synthetic amyloid beta peptide: Isoform-specific effects and implications for late-onset Alzheimer disease
18. Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues
19. Immune system response in Alzheimer's disease
20. A4 protein in Alzheimer's disease: Primary and secondary cellular events in extracellular amyloid deposition
21. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis
22. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid
23. Distribution of clustering in Alzheimer brain tissue
24. Sulfated glycosaminoglycans: A common constituent of all amyloids?
25. Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer's disease
26. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease
27. Alpha 1-antichymotrypsin is associated solely with amyloid deposits containing the beta-protein. Amyloid and cell localization of alpha 1-antichymotrypsin
28. Distribution of the protease inhibitor alpha 1-antichymotrypsin in cerebral and systemic amyloid
29. Aβ-immunization reduces spatial learning impairment and dense cored amyloid plaque burden in an animal model of alzheimer's disease without affecting brain Aβ-peptide levels
30. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections
31. Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro
32. Common core structure of amyloid fibrils by synchrotron X-ray diffraction
33. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous beta-sheet helix
34. Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs
35. Molecular structure of a synthetic Alzheimer's amyloid
36. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing
37. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease
38. On the nucleation and growth of amyloid beta-protein fibrils: Detection of nuclei and quantitation of rate constants
39. The protofilament substructure of amyloid fibrils
40. Oligomerization and fibril assembly of the amyloid-beta protein
41. Amyloid fibril formation from full-length and fragments of amylin
42. In vitro amyloid fibril formation by synthetic peptides corresponding to the amino terminus of apoSAA isoforms from amyloid-susceptible and amyloid-resistant mice
43. Polypeptide chain folding in the hydrophobic core of hamster scrapie prion: Analysis by X-ray diffraction
44. Morphology and antibody recognition of synthetic beta-amyloid peptides
45. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease
46. Manipulating the amyloid-β aggregation pathway with chemical chaperones
47. The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation
48. Solvent effects on self-assembly of beta-amyloid peptide
49. The Alzheimer's peptide Aβ adopts a collapsed coil structure in water
50. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease
51. Protein solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is?
52. Solution structures of micelle-bound amyloid beta-(l-40) and beta(1-42) peptides of Alzheimer's disease
53. pH-dependent structural transitions of Aizheimer amyloid peptides
54. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation
55. Structure of beta-crystallite assemblies formed by Alzheimer beta-amyloid protein analogues: Analysis by x-ray diffraction
56. Structural analysis of Alzheimer's beta (1-40) amyloid: Protofilament assembly of tubular fibrils
57. "Cross-beta" conformation in proteins
58. Direct visualisation of the β-sheet structure of synthetic Alzheimer's amyloid
59. Structural origins of diamagnetic anisotropy in proteins
60. Molecular determinants of amyloid deposition in Alzheimer's disease: Conformational studies of synthetic beta-protein fragments
61. Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide
62. Arrest of beta-amyloid fibril formation by a pentapeptide ligand
63. A molecular model of Alzheimer amyloid beta-peptide fibril formation
64. Modified-peptide inhibitors of amyloid beta-peptide polymerization
65. Propagating structure of Alzheimer's beta-amyloid (10-35) is parallel beta-sheet with residues in exact register
66. Two-dimensional structure of beta-amyloid (10-35) fibrils
67. Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation
68. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease
69. Identification in immunolocalization of a new class of proteoglycan (keratan sulfate) to the neuritic plaques of Alzheimer's disease
70. Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease
71. Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease
72. Interactions of Aβ peptides with glycosaminoglycans: Effects on fibril nucleation and growth
73. Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide
74. Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide
75. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease
76. pH-dependent binding of synthetic β-amyloid peptides to glycosaminoglycans
77. Congo red inhibits proteoglycan and serum amyloid P binding to amyloid-β fibrils
78. Perlecan binds to the β-amyloid proteins (Aβ) of Alzheimer's disease, accelerates Aβ fibril formation, and maintains Aβ fibril stability
79. Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: Implications for amyloid fibril-proteoglycan interactions
80. Heparin-binding properties of the amyloidogenic peptides Abeta and amylin
81. Transgenic mouse models of Alzheimer's disease
82. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes
83. An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease
84. Cerebral amyloid angiopathy: Amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease
85. Co-deposition of basement membrane components during the induction of murine AA amyloid
86. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis
87. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease